OncoMatch/Clinical Trials/NCT06436976
The Effect of Probiotics ATG-F4 in Cancer Patients
Is NCT06436976 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies LT-002 (Lactobacillus reuteri ATG-F4 for pancreatic cancer.
Treatment: LT-002 (Lactobacillus reuteri ATG-F4 — Patients with advanced colorectal cancer or pancreatic cancer who are receiving oxaliplatin-based chemotherapy will be included. The research participants in this study will consume probiotics along with safety and anti-cancer agent side effect-related questionnaires, blood, and fecal sample collection for up to 12 weeks from the date of registration. The total duration of participation for research subjects is 12 weeks.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Colorectal Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy (oxaliplatin) — current
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify